Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BLAM- A phase IIb study of Blinatumomab + Cytarabine (AraC) and Methotrexate in adult B-precursor Acute Lymphoblastic Leukaemia

Next Previous
Trial Profile

BLAM- A phase IIb study of Blinatumomab + Cytarabine (AraC) and Methotrexate in adult B-precursor Acute Lymphoblastic Leukaemia

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 25 Jul 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Blinatumomab (Primary) ; Cyclophosphamide; Cytarabine; Cytarabine; Dexamethasone; Hydrocortisone; Mercaptopurine; Methotrexate; Methotrexate; Methotrexate; Methylprednisolone; Prednisolone; Vincristine; Vincristine
  • Indications Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Proof of concept; Therapeutic Use
  • Acronyms BLAM

    • Most Recent Events

    • 15 Jun 2023 Results of an analysis of the final endpoint at 14 Feb 2023; n=30 presented at the 28th Congress of the European Haematology Association
    • 14 Dec 2021 Interim results (n=30 ) presented at the 63rd American Society of Hematology Annual Meeting and Exposition
    • 06 Nov 2019 Results assessing response to therapy of the first 10 patients enrolled on this study, released in 61st Annual Meeting and Exposition of the American Society of Hematology
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top